IDG is combating antibiotic resistance by combining epidemiological big data with precision diagnostics.
Our process mitigates patient risk and generates favorable outcomes.
Our researchers have identified CLoNeT™, a set of unique bacterial barcodes that quickly identify resistant bacteria in patient samples. First-generation CLoNeT™ tests target urinary tract infections, which are at the forefront of the drug resistance crisis.
Our big data platform,BactNeT™, links bacterial samples, IDG’s proprietary barcodes, and clinical information with responses to commonly prescribed antibiotics.
Together with CLoNeT™, BactNeT™ forms a state-of-the art epidemiological surveillance network that has the potential to provide transformative solutions and bring the appropriate medicine directly to the patient’s bedside.
Urgent-care clinical trials show that our first generation diagnostic for UTIs, CLoNeT™, yields results in less than 45 minutes, and reduces the rate of antibiotic prescription errors from 25% to less than 3%.